These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8635933)

  • 1. Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy.
    D'Amico AV; Propert KJ
    Int J Radiat Oncol Biol Phys; 1996 May; 35(2):273-9. PubMed ID: 8635933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.
    Lankford SP; Pollack A; Zagars GK
    Int J Radiat Oncol Biol Phys; 1997 May; 38(2):327-33. PubMed ID: 9226319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter.
    D'Amico AV; Whittington R; Kaplan I; Beard C; Schultz D; Malkowicz SB; Wein A; Tomaszewski JE; Coleman CN
    Cancer; 1998 Jan; 82(2):334-41. PubMed ID: 9445191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer.
    Nguyen PL; Whittington R; Koo S; Schultz D; Cote KB; Loffredo M; Tempany CM; Titelbaum DS; Schnall MD; Renshaw AA; Tomaszewski JE; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):400-5. PubMed ID: 15145155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analyzing outcome-based staging for clinically localized adenocarcinoma of the prostate.
    D'Amico AV; Desjardin A; Chen MH; Paik S; Schultz D; Renshaw AA; Loughlin KR; Richie JP
    Cancer; 1998 Nov; 83(10):2172-80. PubMed ID: 9827722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
    Lee WR; Hanlon AL; Hanks GE
    J Urol; 1996 Aug; 156(2 Pt 1):450-3. PubMed ID: 8683700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.
    Beard CJ; Chen MH; Cote K; Loffredo M; Renshaw AA; Hurwitz M; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):19-24. PubMed ID: 14697416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.
    Kuban DA; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Zietman AL
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):915-28. PubMed ID: 14575822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
    Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
    Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial.
    Pollack A; Zagars GK; Antolak JA; Kuban DA; Rosen II
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):677-85. PubMed ID: 12377318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic biopsies: do they add prognostic information in men with clinically localized prostate cancer treated with radiation therapy alone?
    Lee WR; Hanlon AL; Hanks GE
    Radiology; 1996 Feb; 198(2):439-42. PubMed ID: 8596846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer.
    D'Amico AV; Schultz D; Silver B; Henry L; Hurwitz M; Kaplan I; Beard CJ; Renshaw AA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):679-84. PubMed ID: 11172949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy.
    Kestin LL; Vicini FA; Ziaja EL; Stromberg JS; Frazier RC; Martinez AA
    Cancer; 1999 Oct; 86(8):1557-66. PubMed ID: 10526285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasonic volume monitoring in patient with prostate cancer treated by external beam radiation therapy.
    Saitoh M; Ramirez E; Babaian RJ
    Urology; 1994 Mar; 43(3):342-8. PubMed ID: 7510913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml.
    D'Amico AV; Whittington R; Kaplan I; Beard C; Jiroutek M; Malkowicz SB; Wein A; Coleman CN
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1053-8. PubMed ID: 9169812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.